Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.

Seront, Emmanuel; Catala, Gaëtan; Dermine, Alexandre; Lejeune, Sarah; Rysselinck, Stephane

Seront, Emmanuel; Catala, Gaëtan; Dermine, Alexandre; Lejeune, Sarah; Rysselinck, Stephane.

Afiliação

Seront E; Department of Medical Oncology, Hopital de Jolimont, 7100 Haine Saint Paul, Belgium.
Catala G; Department of Medical Oncology, Hopital de Jolimont, 7100 Haine Saint Paul, Belgium.
Dermine A; Department of Medical Oncology, Hopital de Jolimont, 7100 Haine Saint Paul, Belgium.
Lejeune S; Department of Medical Oncology, Hopital de Jolimont, 7100 Haine Saint Paul, Belgium.
Rysselinck S; Department of Medical Oncology, Hopital de Jolimont, 7100 Haine Saint Paul, Belgium.

Future Sci OA ; 4(10): FSO341, 2018 Dec.

Article em En | MEDLINE | ID: mdl-30457576

Palavras-chave

atezolizumab; avelumab; durvalumab; gene signature; immune checkpoint inhibitors; immunotherapy; nivolumab; pembrolizumab; programmed death ligand-1 (PD-L1); urothelial carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Future Sci OA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google